Showing 3851-3860 of 9301 results for "".
- Baby Dove Doubles Down Efforts to Close the Maternal Care Gap with #DearDoula and Greater Investment in Black Birth Equity Fundhttps://practicaldermatology.com/news/baby-dove-doubles-down-efforts-to-close-the-maternal-care-gap-with-deardoula-and-greater-investment-in-black-birth-equity-fund/2461342/Baby Dove is expanding the Black Birth Equity Fund, launching a new informative series called #DearDoula, and reinforcing existing strategic partnerships to help close the significant gap in care and health outcomes for Black mothers and their babies. "As a brand that encourages all parents to car…
- Dermatologists Must Help Fight Climate Changehttps://practicaldermatology.com/news/dermatologists-must-help-fight-climate-change/2461339/Dermatologists should engage more meaningfully on key climate issues and to move beyond discussions of the skin-related impacts of climate change, according to a commentary in the International Journal of Dermatology. The authors note that they and other dermatologists are professionally charged w…
- Dermalogica Gives Back: Brand Launches Grant Program to Empower the Next Generation of Industry Proshttps://practicaldermatology.com/news/dermalogica-gives-back-brand-launches-grant-program-to-empower-the-next-generation-of-industry-pros/2461337/Dermalogica is offering a new grant program for non-profit organizations that help give greater access to skillset training in the United States. The grant program is now accepting applications and supports education, mentorship, and skills training for non-profits training therapists in the US. …
- EADV 2022 News: Otezla Works Well in Kids with PsO, Adults with Genital PsOhttps://practicaldermatology.com/news/eadv-2022-news-otezla-works-well-in-kids-with-pso-adults-with-genital-pso/2461332/Otezla (apremilast) performs well in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, according to new research presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy. The SPROUT stu…
- Game On: IFPA Launches the “Explore Psoriatic Disease Together” Campaign to Build the IFPA Island on Animal Crossing: New Horizonshttps://practicaldermatology.com/news/game-on-ifpa-launches-the-explore-psoriatic-disease-together-campaign-to-build-the-ifpa-island-on-animal-crossing-new-horizons/2461328/The International Federation of Psoriatic Disease Associations (IFPA) is launching a campaign to build the IFPA Island on the Nintendo video game, Animal Crossing: New Horizons. This new campaign is called “Explore Psoriatic Disease Together” and calls on the psoriatic disease community to help bu…
- Psoriasis, Other Autoimmune Diseases Up Risk for CVDhttps://practicaldermatology.com/news/psoriasis-other-autoimmune-diseases-up-risk-for-cvd/2461323/Earlier research has suggested associations between some autoimmune disorders and a higher risk of cardiovascular disease, and now, a new study shows that nineteen of the most common autoimmune disorders seem to increase risk for developing heart disease. Patients with autoimmune disease have a s…
- Arcutis Rolls Out New Psoriasis Public Awareness Campaignhttps://practicaldermatology.com/news/arcutis-rolls-out-new-psoriasis-public-awareness-campaign/2461321/Arcutis Biotherapeutics, Inc. is launching an educational campaign designed to raise awareness about the physical and emotional impact of plaque psoriasis and empower those living with the disease to have open, honest conversations with their healthcare providers, family, and friends. The campaig…
- Cutera Recognized by 50/50 Women on Boards for Gender-Balanced Board of Directorshttps://practicaldermatology.com/news/cutera-recognized-by-5050-women-on-boards-for-gender-balanced-board-of-directors/2461315/The 50/50 Women on Boards recognized Cutera for having a gender-balanced board. With four women directors, holding 50 percent of its corporate board seats, Cutera, Inc. is one of only 8 percent (just 241) of Russell 3000 companies with a gender-balanced board. “We are honored to be recognized b…
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 …
- New Time-Limited Double Allē Points Promotion Launched for Juvederm Usershttps://practicaldermatology.com/news/new-double-alle-points-promotion-for-juvederm-users/2461307/Consumers can earn double points in Allē, Allergan Aesthetics' loyalty rewards program, when treated with two or three syringes from the JUVÉDERM Collection of Fillers during the same visit. Allē points can be redeemed for future Allē-eligible treatments or products. The promotion runs through F…